Mikhail Blagosklonny is an editor, educator, and a scientist. More specifically, his scientific fields of study are life extension and cancer at https://en.wikipedia.org/wiki/Mikhail_Blagosklonny. He is a professor of oncology who teaches at the Roswell Park Cancer Institute In New York. He also editor-in-chief of such publications as “Aging”, “Cell Cycle” and “Oncotarget”.
Mikhail Blagosklonny became an associate professor of medicine at New York Medical College in Valhalla, in 2002. This was prior to his working as one of the senior scientists at Ordway Research Institute located in Albany, New York. In 2009 he signed on to be the professor of oncology at the Roswell Park Cancer Institute.
Aging And Rapamycin
He has a theory on impactjournals.com concerning a possible relationship between cancer, TOR signaling in aging and the use of rapamycin which is cancer drug. He believes the popular drug could be used to not only treat cancer but also to extend life in general. He is reportedly one of the most aggressive supporters for the use of the drug in the field of longevity research.
Blagosklonny holds multiple degrees on nature.com. He earned both a Ph.D. in experimental medicine and cardiology and an M.D. in internal medicine from the First Pavlov State Medical University of St. Petersburg.
Editorial Activities And Publications
In addition to being the editor-in-chief of the three previously mentioned journals, he is involved with other publications as well. Mikhail Blagosklonny is the associate editor of “Cancer Biology & Therapy”. Additionally, he is a member of the editorial board for “Cell Death & Differentiation.
Mikhail Blogosklonny’s scientific research interests anti-aging drugs, biogerontology (the specific mechanisms of aging, cancer in general and targeted cancer therapies that also protect normal cells from any and all damage. His other interests include overall health, publishing and income empowerment.